Ironwood Pharmaceuticals, Inc.
IRWD
Jodie situation report
Ironwood Pharmaceuticals, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 13 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.
- IRWD's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if IRWD's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind IRWD
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ABBVAbbVie Inc.partnerMay 7, 2026 ▾
“Linaclotide is available under the trademarked name CONSTELLA ® for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.”
AZNAstraZeneca PLCpartnerMay 7, 2026 ▾
“ther with its affiliates, AstraZeneca in China (including Hong Kong and Macau), and Astellas Pharma Inc., or Astellas, in Japan.”
ARDXArdelyx, Inc.competitorFeb 26, 2026 ▾
“Ardelyx, Inc.’s, or Ardelyx, IBSRELA™ (tenapanor), is approved by the U.S.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
IRWD is currently a Follower in the organic co-movement group Regional Financial Services. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for IRWD; it is not active in the latest market snapshot.